A Warburg Pincus-led consortium completed the $597m investment in Polyplus.

A Warburg Pincus-led consortium completed the $597m in Polyplus, a developer of biotechnology used in gene and cell therapy. The investment is alongside existing majority shareholder, ArchiMed, a European private equity healthcare specialist. “The investment will enable us to further expand production capacity, fuel continued innovation in products, and support key growth initiatives. We’ll also focus on international expansion and increased hiring across technical, regulatory and commercial support functions,” Karsten Wilking, Polyplus CEO.